

# Weijian Guo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/227173/publications.pdf>

Version: 2024-02-01

79  
papers

2,021  
citations

430874

18  
h-index

265206

42  
g-index

79  
all docs

79  
docs citations

79  
times ranked

2964  
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases. <i>Frontiers in Oncology</i> , 2022, 12, 747124.	2.8	3
2	FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	3.2	9
3	Integrated DNA and RNA sequencing reveals early drivers involved in metastasis of gastric cancer. <i>Cell Death and Disease</i> , 2022, 13, 392.	6.3	7
4	A phase I study of TST001, a high affinity humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4062-4062.	1.6	2
5	Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110390.	3.2	2
6	Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	3.0	2
7	A prospective phase II study of raltitrexed combined with Sâ€1 as salvage treatment for patients with refractory metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 513-521.	1.1	4
8	Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 547-557.	2.0	9
9	Subgroup analysis by prior anti-VEGFor anti-EGFR target therapy in FRESCO,a randomized, double-blind, Phase IIIâ€rial. <i>Future Oncology</i> , 2021, 17, 1339-1350.	2.4	5
10	Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in theâ€FRESCO trial. <i>Future Oncology</i> , 2021, 17, 1923-1931.	2.4	2
11	Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin,) Tj ETQq1 1 0.784314 rgBT /Ove <i>Journal of Clinical Oncology</i> , 2021, 39, 4014-4014.	1.6	2
12	Integrated DNA and RNA sequencing to reveal early drivers of metastasis in gastric cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16096-e16096.	1.6	0
13	Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16037-e16037.	1.6	0
14	XELOX or mFOLFOX6 chemotherapy combined with resection of primary lesion versus chemotherapy alone for colon cancer with unresectable metastases: A randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3590-3590.	1.6	0
15	Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16034-e16034.	1.6	0
16	Subcutaneous envafolelimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 95.	17.0	50
17	AKP and GGT level can provide an early prediction of first-line treatment efficacy in colorectal cancer patients with hepatic metastases. <i>Biomarkers in Medicine</i> , 2021, 15, 697-713.	1.4	4
18	Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4439-4450.	2.0	1

#	ARTICLE	IF	CITATIONS
19	Development and validation of nomograms for prediction of overall survival and cancer-specific survival of patients of colorectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 261-269.	1.3	5
20	Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer. <i>Cancer Medicine</i> , 2020, 9, 9052-9063.	2.8	77
21	Predictive model for risk of gastric cancer using genetic variants from genome-wide association studies and high-evidence meta-analysis. <i>Cancer Medicine</i> , 2020, 9, 7310-7316.	2.8	9
22	EZH2: a novel target for cancer treatment. <i>Journal of Hematology and Oncology</i> , 2020, 13, 104.	17.0	447
23	Functional variation of SLC52A3 rs13042395 predicts survival of Chinese gastric cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12550-12559.	3.6	2
24	<i>MUC4</i> , <i>MUC16</i> , and <i>TTN</i> genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e155.	4.0	80
25	Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial. <i>Advances in Therapy</i> , 2020, 37, 4585-4598.	2.9	8
26	Microsatellite Instability-Related <i>ACVR2A</i> Mutations Partially Account for Decreased Lymph Node Metastasis in MSI-H Gastric Cancers. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3809-3821.	2.0	8
27	miR-345 inhibits migration and stem-like cell phenotype in gastric cancer via inactivation of Rac1 by targeting EPS8. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 52, 259-267.	2.0	8
28	Comparison of intravoxel incoherent motion imaging, diffusion kurtosis imaging, and conventional DWI in predicting the chemotherapeutic response of colorectal liver metastases. <i>European Journal of Radiology</i> , 2020, 130, 109149.	2.6	12
29	Severe loss of visceral fat and skeletal muscle after chemotherapy predicts poor prognosis in metastatic gastric cancer patients without gastrectomy. <i>Journal of Cancer</i> , 2020, 11, 3310-3317.	2.5	13
30	Early carcinoembryonic antigen (CEA) dynamics to predict fruquintinib efficacy in FRESCO, a 3+ line metastatic colorectal carcinoma (mCRC) phase III trial. <i>Journal of Clinical Oncology</i> , 2020, 38, e16001-e16001.	1.6	1
31	TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy. <i>Aging</i> , 2020, 12, 14556-14568.	3.1	20
32	FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4038-4038.	1.6	3
33	Envafolelimab (KN035) in advanced tumors with mismatch-repair deficiency. <i>Journal of Clinical Oncology</i> , 2020, 38, 3021-3021.	1.6	3
34	Diffusion kurtosis imaging in predicting the chemotherapeutic response of colorectal liver metastases: The result of the FDZL-MRinCLM study. <i>Journal of Clinical Oncology</i> , 2020, 38, e16034-e16034.	1.6	0
35	Impact of cetuximab sequence on progress-free survival (PFS) and overall survival (OS) in patients with RAS wild-type metastatic colorectal cancer (mCRC): A real-world study. <i>Journal of Clinical Oncology</i> , 2020, 38, e16042-e16042.	1.6	0
36	A phase II study of apatinib treatment for advanced biliary tract carcinoma after failure of the standard chemotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, e16684-e16684.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Integrin $\alpha_5\beta_1$ /Akt/Sp1 pathway participates in matrix stiffness-mediated effects on VEGFR2 upregulation in vascular endothelial cells. <i>American Journal of Cancer Research</i> , 2020, 10, 2635-2648.	1.4	3
38	Functional variant of <i>MTOR</i> rs2536 and survival of Chinese gastric cancer patients. <i>International Journal of Cancer</i> , 2019, 144, 251-262.	5.1	5
39	Development and validation of nomograms for prediction of overall survival and cancer-specific survival of patients with Stage IV colorectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 438-446.	1.3	22
40	Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 4054-4054.	1.6	2
41	Oncogenic alterations detected by droplet digital PCR in patients with metastatic colorectal cancer resistant to cetuximab. <i>Journal of Clinical Oncology</i> , 2019, 37, 575-575.	1.6	1
42	Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial. <i>Journal of Clinical Oncology</i> , 2019, 37, e15012-e15012.	1.6	2
43	Protocadherin-8 promotes invasion and metastasis via laminin subunit $\beta_2$ in gastric cancer. <i>Cancer Science</i> , 2018, 109, 732-740.	3.9	30
44	The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter. <i>Journal of Hematology and Oncology</i> , 2018, 11, 9.	17.0	94
45	Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. <i>Biomarker Research</i> , 2018, 6, 10.	6.8	276
46	BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 355-361.	2.0	14
47	Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy. <i>Oncology Letters</i> , 2018, 16, 4489-4497.	1.8	0
48	Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2486.	7.4	202
49	The prognostic value of age in non-metastatic gastric cancer after gastrectomy: a retrospective study in the U.S. and China. <i>Journal of Cancer</i> , 2018, 9, 1188-1199.	2.5	16
50	MiR-486 promotes proliferation and suppresses apoptosis in myeloid cells by targeting Cebpa in vitro. <i>Cancer Medicine</i> , 2018, 7, 4627-4638.	2.8	17
51	Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 $\pm$ cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3521-3521.	1.6	3
52	Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2018, 36, 3537-3537.	1.6	1
53	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3544-3544.	1.6	1
54	A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with metastatic colorectal cancer after failure of standard chemotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, e15558-e15558.	1.6	1

#	ARTICLE	IF	CITATIONS
55	A phase II study of irinotecan as single agent in the third-line treatment of unresectable or metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16084-e16084.	1.6	1
56	Gender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer. <i>Carcinogenesis</i> , 2017, 38, 837-846.	2.8	30
57	A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer. <i>BMC Cancer</i> , 2017, 17, 188.	2.6	8
58	VPS52 induces apoptosis via cathepsin D in gastric cancer. <i>Journal of Molecular Medicine</i> , 2017, 95, 1107-1116.	3.9	12
59	Influence of hypoxia-related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF. <i>Oncology Letters</i> , 2017, 15, 1334-1342.	1.8	1
60	A retrospective study of raltitrexed combined with S-1 as salvage treatment for patients with metastatic colorectal cancer after failure of standard chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15066-e15066.	1.6	2
61	A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 128-128.	1.6	7
62	Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study. <i>Oncotarget</i> , 2017, 8, 37826-37834.	1.8	11
63	Differential microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer. <i>Oncotarget</i> , 2017, 8, 35783-35791.	1.8	29
64	The influence of marital status on the stage at diagnosis, treatment, and survival of adult patients with gastric cancer: a population-based study. <i>Oncotarget</i> , 2017, 8, 22385-22405.	1.8	37
65	Preliminary analysis of FOLFIRI regimen with or without bevacizumab as second-line systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 469-469.	1.6	0
66	Comparison of efficacy and safety of first-line palliative chemotherapy with TX and XELOX regimens in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4070-4070.	1.6	0
67	Early presence of antiangiogenesis-related adverse events as a potential biomarker of antitumor efficacy in patients with metastatic gastric cancer treated with apatinib.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4052-4052.	1.6	0
68	Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs. <i>Journal of Hematology and Oncology</i> , 2016, 9, 90.	17.0	53
69	MicroRNA expression profiles of granulocytic myeloid-derived suppressor cells from mice bearing Lewis lung carcinoma. <i>Molecular Medicine Reports</i> , 2016, 14, 4567-4574.	2.4	6
70	The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1603-1610.	7.0	37
71	Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy. <i>Tumor Biology</i> , 2016, 37, 1753-1762.	1.8	9
72	Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer. <i>Oncotarget</i> , 2016, 7, 9815-9831.	1.8	90

#	ARTICLE	IF	CITATIONS
73	Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer. <i>Oncotarget</i> , 2016, 7, 22733-22745.	1.8	12
74	Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. <i>Oncotarget</i> , 2015, 6, 40519-40534.	1.8	16
75	miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. <i>Oncotarget</i> , 2015, 6, 24448-24462.	1.8	76
76	Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen. <i>Oncotarget</i> , 2015, 6, 39018-39027.	1.8	17
77	Angiotensin-converting enzyme insertion/deletion polymorphism and gastric cancer: a systematic review and meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 5788-93.	1.3	2
78	Oxidative Stress-Related Genetic Polymorphisms Are Associated with the Prognosis of Metastatic Gastric Cancer Patients Treated with Epirubicin, Oxaliplatin and 5-Fluorouracil Combination Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e116027.	2.5	22
79	Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. <i>Human Immunology</i> , 2014, 75, 1128-1137.	2.4	55